Gliclazide

Product Name:Gliclazide

Another Name:

CAS:244-260-5,21187-98-4

Molecular Weight:323.4105

Molecular Formula:C15H21N3O3S

The pharmacological effects of product is a second-generation sulfonylurea oral hypoglycemic agents hypoglycemic effect on normal subjects and patients with diabetes have. The hypoglycemic strength between tolbutamide and glibenclamide.This product is mainly the direct effect on the pancreas, to promote Ca transport to pancreatic β cells, stimulate insulin secretion. In the same time, but also can improve the surrounding tissue for glucose metabolism, thereby reducing blood sugar.

In addition, the product can inhibit platelet release of arachidonic acid from phospholipids, thereby reducing thromboxane (TXA3), synthesis, inhibition variety of coagulation factors (Ⅴ, VIII and XI), and increased plasmin plasminogen activator factor level, and promote the dissolution of fibrin. The animal studies also found that the product can reduce plasma cholesterol, triglyceride and fatty acid levels.

Edit this paragraph indications apply to with diet to control efficacy dissatisfied light, moderate, non-insulin-dependent diabetes mellitus, patients with pancreatic B cells secrete insulin reactive β-cells

Energy, and no serious complications. Mainly used for adult onset with diet alone control ineffective, and non-ketosis tendency to light, medium diabetes. But also to improve diabetic retinopathy, and metabolism, vascular function disorders. Together with biguanide oral hypoglycemic agents for alone can not control patients, combined treatment of insulin-dependent diabetes mellitus and insulin can reduce the amount of insulin.